Selected research
Industry Research
AL Amyloidosis Therapeutics Industry Research Report 2026
Market perspective
The global AL Amyloidosis Therapeutics market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the AL Amyloidosis Therapeutics market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the AL Amyloidosis Therapeutics market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the AL Amyloidosis Therapeutics market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of AL Amyloidosis Therapeutics include Janssen Pharmaceutical, Pfizer, GlaxoSmithKline Pharmaceuticals Ltd, Bristol-Myers Squibb, Spectrum Pharmaceuticals, Inc., Prothena, Oncopeptides AB, Eidos Therapeutics, Inc. and Corino Therapeutics, Inc. and among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global AL Amyloidosis Therapeutics market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to AL Amyloidosis Therapeutics.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
AL Amyloidosis Therapeutics Market by Company
Janssen Pharmaceutical
Pfizer
GlaxoSmithKline Pharmaceuticals Ltd
Bristol-Myers Squibb
Spectrum Pharmaceuticals, Inc.
Prothena
Oncopeptides AB
Eidos Therapeutics, Inc.
Corino Therapeutics, Inc.
Alexion Pharmaceuticals
AL Amyloidosis Therapeutics Segment by Type
Chemotherapy
Supportive Care
Surgery
Stem Cell Transplant
Targeted Therapy
AL Amyloidosis Therapeutics Segment by Application
Clinics
Hospitals
Ambulatory Service Centres
Others
AL Amyloidosis Therapeutics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global AL Amyloidosis Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of AL Amyloidosis Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of AL Amyloidosis Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of AL Amyloidosis Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Chemotherapy
- Supportive Care
- Surgery
- Stem Cell Transplant
- Targeted Therapy
Applications
- Clinics
- Hospitals
- Ambulatory Service Centres
- Others
Companies covered
- Janssen Pharmaceutical
- Pfizer
- GlaxoSmithKline Pharmaceuticals Ltd
- Bristol-Myers Squibb
- Spectrum Pharmaceuticals, Inc.
- Prothena
- Oncopeptides AB
- Eidos Therapeutics, Inc.
- Corino Therapeutics, Inc.
- Alexion Pharmaceuticals
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 AL Amyloidosis Therapeutics by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Chemotherapy
- 2.2.3 Supportive Care
- 2.2.4 Surgery
- 2.2.5 Stem Cell Transplant
- 2.2.6 Targeted Therapy
- 2.3 AL Amyloidosis Therapeutics by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Clinics
- 2.3.3 Hospitals
- 2.3.4 Ambulatory Service Centres
- 2.3.5 Others
- 2.4 Assumptions and Limitations
3 AL Amyloidosis Therapeutics Breakdown Data by Type
- 3.1 Global AL Amyloidosis Therapeutics Historic Market Size by Type (2021-2026)
- 3.2 Global AL Amyloidosis Therapeutics Forecasted Market Size by Type (2027-2032)
4 AL Amyloidosis Therapeutics Breakdown Data by Application
- 4.1 Global AL Amyloidosis Therapeutics Historic Market Size by Application (2021-2026)
- 4.2 Global AL Amyloidosis Therapeutics Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global AL Amyloidosis Therapeutics Market Perspective (2021-2032)
- 5.2 Global AL Amyloidosis Therapeutics Growth Trends by Region
- 5.2.1 Global AL Amyloidosis Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 AL Amyloidosis Therapeutics Historic Market Size by Region (2021-2026)
- 5.2.3 AL Amyloidosis Therapeutics Forecasted Market Size by Region (2027-2032)
- 5.3 AL Amyloidosis Therapeutics Market Dynamics
- 5.3.1 AL Amyloidosis Therapeutics Industry Trends
- 5.3.2 AL Amyloidosis Therapeutics Market Drivers
- 5.3.3 AL Amyloidosis Therapeutics Market Challenges
- 5.3.4 AL Amyloidosis Therapeutics Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top AL Amyloidosis Therapeutics Players by Revenue
- 6.1.1 Global Top AL Amyloidosis Therapeutics Players by Revenue (2021-2026)
- 6.1.2 Global AL Amyloidosis Therapeutics Revenue Market Share by Players (2021-2026)
- 6.2 Global AL Amyloidosis Therapeutics Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of AL Amyloidosis Therapeutics Head Office and Area Served
- 6.4 Global AL Amyloidosis Therapeutics Players, Product Type & Application
- 6.5 Global AL Amyloidosis Therapeutics Manufacturers Established Date
- 6.6 Global AL Amyloidosis Therapeutics Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America AL Amyloidosis Therapeutics Market Size (2021-2032)
- 7.2 North America AL Amyloidosis Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America AL Amyloidosis Therapeutics Market Size by Country (2021-2026)
- 7.4 North America AL Amyloidosis Therapeutics Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe AL Amyloidosis Therapeutics Market Size (2021-2032)
- 8.2 Europe AL Amyloidosis Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe AL Amyloidosis Therapeutics Market Size by Country (2021-2026)
- 8.4 Europe AL Amyloidosis Therapeutics Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific AL Amyloidosis Therapeutics Market Size (2021-2032)
- 9.2 Asia-Pacific AL Amyloidosis Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific AL Amyloidosis Therapeutics Market Size by Country (2021-2026)
- 9.4 Asia-Pacific AL Amyloidosis Therapeutics Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America AL Amyloidosis Therapeutics Market Size (2021-2032)
- 10.2 South America AL Amyloidosis Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America AL Amyloidosis Therapeutics Market Size by Country (2021-2026)
- 10.4 South America AL Amyloidosis Therapeutics Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa AL Amyloidosis Therapeutics Market Size (2021-2032)
- 11.2 Middle East & Africa AL Amyloidosis Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa AL Amyloidosis Therapeutics Market Size by Country (2021-2026)
- 11.4 Middle East & Africa AL Amyloidosis Therapeutics Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Janssen Pharmaceutical
- 12.1.1 Janssen Pharmaceutical Company Information
- 12.1.2 Janssen Pharmaceutical Business Overview
- 12.1.3 Janssen Pharmaceutical Revenue in AL Amyloidosis Therapeutics Business (2021-2026)
- 12.1.4 Janssen Pharmaceutical AL Amyloidosis Therapeutics Product Portfolio
- 12.1.5 Janssen Pharmaceutical Recent Developments
- 12.2 Pfizer
- 12.2.1 Pfizer Company Information
- 12.2.2 Pfizer Business Overview
- 12.2.3 Pfizer Revenue in AL Amyloidosis Therapeutics Business (2021-2026)
- 12.2.4 Pfizer AL Amyloidosis Therapeutics Product Portfolio
- 12.2.5 Pfizer Recent Developments
- 12.3 GlaxoSmithKline Pharmaceuticals Ltd
- 12.3.1 GlaxoSmithKline Pharmaceuticals Ltd Company Information
- 12.3.2 GlaxoSmithKline Pharmaceuticals Ltd Business Overview
- 12.3.3 GlaxoSmithKline Pharmaceuticals Ltd Revenue in AL Amyloidosis Therapeutics Business (2021-2026)
- 12.3.4 GlaxoSmithKline Pharmaceuticals Ltd AL Amyloidosis Therapeutics Product Portfolio
- 12.3.5 GlaxoSmithKline Pharmaceuticals Ltd Recent Developments
- 12.4 Bristol-Myers Squibb
- 12.4.1 Bristol-Myers Squibb Company Information
- 12.4.2 Bristol-Myers Squibb Business Overview
- 12.4.3 Bristol-Myers Squibb Revenue in AL Amyloidosis Therapeutics Business (2021-2026)
- 12.4.4 Bristol-Myers Squibb AL Amyloidosis Therapeutics Product Portfolio
- 12.4.5 Bristol-Myers Squibb Recent Developments
- 12.5 Spectrum Pharmaceuticals, Inc.
- 12.5.1 Spectrum Pharmaceuticals, Inc. Company Information
- 12.5.2 Spectrum Pharmaceuticals, Inc. Business Overview
- 12.5.3 Spectrum Pharmaceuticals, Inc. Revenue in AL Amyloidosis Therapeutics Business (2021-2026)
- 12.5.4 Spectrum Pharmaceuticals, Inc. AL Amyloidosis Therapeutics Product Portfolio
- 12.5.5 Spectrum Pharmaceuticals, Inc. Recent Developments
- 12.6 Prothena
- 12.6.1 Prothena Company Information
- 12.6.2 Prothena Business Overview
- 12.6.3 Prothena Revenue in AL Amyloidosis Therapeutics Business (2021-2026)
- 12.6.4 Prothena AL Amyloidosis Therapeutics Product Portfolio
- 12.6.5 Prothena Recent Developments
- 12.7 Oncopeptides AB
- 12.7.1 Oncopeptides AB Company Information
- 12.7.2 Oncopeptides AB Business Overview
- 12.7.3 Oncopeptides AB Revenue in AL Amyloidosis Therapeutics Business (2021-2026)
- 12.7.4 Oncopeptides AB AL Amyloidosis Therapeutics Product Portfolio
- 12.7.5 Oncopeptides AB Recent Developments
- 12.8 Eidos Therapeutics, Inc.
- 12.8.1 Eidos Therapeutics, Inc. Company Information
- 12.8.2 Eidos Therapeutics, Inc. Business Overview
- 12.8.3 Eidos Therapeutics, Inc. Revenue in AL Amyloidosis Therapeutics Business (2021-2026)
- 12.8.4 Eidos Therapeutics, Inc. AL Amyloidosis Therapeutics Product Portfolio
- 12.8.5 Eidos Therapeutics, Inc. Recent Developments
- 12.9 Corino Therapeutics, Inc.
- 12.9.1 Corino Therapeutics, Inc. Company Information
- 12.9.2 Corino Therapeutics, Inc. Business Overview
- 12.9.3 Corino Therapeutics, Inc. Revenue in AL Amyloidosis Therapeutics Business (2021-2026)
- 12.9.4 Corino Therapeutics, Inc. AL Amyloidosis Therapeutics Product Portfolio
- 12.9.5 Corino Therapeutics, Inc. Recent Developments
- 12.10 Alexion Pharmaceuticals
- 12.10.1 Alexion Pharmaceuticals Company Information
- 12.10.2 Alexion Pharmaceuticals Business Overview
- 12.10.3 Alexion Pharmaceuticals Revenue in AL Amyloidosis Therapeutics Business (2021-2026)
- 12.10.4 Alexion Pharmaceuticals AL Amyloidosis Therapeutics Product Portfolio
- 12.10.5 Alexion Pharmaceuticals Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst